Biogen Seeks FDA Nod For Oral BG-12 To Treat Multiple Sclerosis - Quick Facts

Biogen Idec To Present At 2013 Deutsche Bank BioFEST; Webcast At 10:45 AM ET

Biogen Idec Gets Notification From FDA On PDUFA Date Extension For ALPROLIX

Biogen Idec Inc. (BIIB) Has Risen To Another New High

Biogen Idec Inc. (BIIB) Broke Out To A New High After TECFIDERA Determination

Trade BIIB now with

2/28/2012 8:13 AM ET

Biogen Idec (BIIB: Quote) said it has submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for marketing approval of BG-12 (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis, or MS.

The company stated that the regulatory submission was based on BG-12's comprehensive development program, in which BG-12 demonstrated significant reductions in MS disease activity coupled with favorable safety and tolerability in the Phase 3 DEFINE and CONFIRM studies.

Biogen noted that it intends to submit a Marketing Authorisation Application for BG-12 to the European Medicines Agency within the coming days.

Click here to receive FREE breaking news email alerts for Biogen Idec and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 141 Articles

Editors Pick

Delta Says No To In-Flight Cell Phone Calls

The federal government may soon be OK with people making in-flight cell phone calls, but Delta Airlines is not. The airline will not allow cellular calls or internet-based voice communications onboard its flights, Delta announced Thursday. The Federal Communications Commission has been asking airlines...

Target Confirms Massive Credit Card Security Breach

Retail giant Target (TGT) on Thursday confirmed that federal authorities are investigating a data breach potentially involving millions of customer credit and debit card records. Hackers apparently had access to accounts used for in-store purchases from the Black Friday holiday shopping weekend through...

Oracle Results Top Estimates

Oracle Corp. said Wednesday after the markets closed that its second quarter profit fell 1% from last year, as higher operating expenses more than offset a 2% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.